• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

葡萄牙首次发现产KPC-3碳青霉烯酶的耐黏菌素和替加环素菌株。

First Description of Colistin and Tigecycline-Resistant Producing KPC-3 Carbapenemase in Portugal.

作者信息

Caneiras Cátia, Calisto Filipa, Jorge da Silva Gabriela, Lito Luis, Melo-Cristino José, Duarte Aida

机构信息

Microbiology and Immunology Department, Interdisciplinary Research Centre Egas Moniz (CiiEM), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal.

Institute of Environmental Health (ISAMB), Faculty of Medicine, Universidade de Lisboa, 1649-028 Lisboa, Portugal.

出版信息

Antibiotics (Basel). 2018 Nov 6;7(4):96. doi: 10.3390/antibiotics7040096.

DOI:10.3390/antibiotics7040096
PMID:30404152
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6315367/
Abstract

Herein, we describe a case report of carbapenem-resistant and isolates that were identified from the same patient at a Tertiary University Hospital Centre in Portugal. Antimicrobial susceptibility and the molecular characterization of resistance and virulence determinants were performed. PCR screening identified the presence of the resistance genes , and in both isolates. The KPC-3 isolate belonged to the ST-14 high risk clone and accumulated an uncommon resistance and virulence profile additional to a horizontal dissemination capacity. In conclusion, the molecular screening led to the first identification of the KPC-3 producer in Portugal with a full antimicrobial resistance profile including tigecycline and colistin.

摘要

在此，我们描述了在葡萄牙一家三级大学医院中心从同一患者身上鉴定出的耐碳青霉烯类菌株的病例报告。进行了抗菌药物敏感性以及耐药性和毒力决定因素的分子特征分析。PCR筛查确定在两种分离株中均存在耐药基因、和。KPC-3分离株属于ST-14高风险克隆，除具有水平传播能力外，还积累了罕见的耐药和毒力谱。总之，分子筛查首次在葡萄牙鉴定出具有包括替加环素和黏菌素在内的完整抗菌药物耐药谱的KPC-3产生菌。

相似文献

1
First Description of Colistin and Tigecycline-Resistant Producing KPC-3 Carbapenemase in Portugal.葡萄牙首次发现产KPC-3碳青霉烯酶的耐黏菌素和替加环素菌株。
Antibiotics (Basel). 2018 Nov 6;7(4):96. doi: 10.3390/antibiotics7040096.
2
Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.意大利单一中心的革兰氏阴性菌中的碳青霉烯和多种药物耐药性：对活性药物体外检测的考虑。
Int J Antimicrob Agents. 2014 Aug;44(2):112-6. doi: 10.1016/j.ijantimicag.2014.04.014. Epub 2014 Jun 2.
3
Molecular characterization of carbapenem-resistant Klebsiella pneumoniae isolates from a university hospital in Brazil.巴西一家大学医院耐碳青霉烯肺炎克雷伯菌分离株的分子特征分析
J Infect Dev Ctries. 2017 Jun 1;11(5):379-386. doi: 10.3855/jidc.8614.
4
Changing epidemiology of KPC-producing Klebsiella pneumoniae in Argentina: Emergence of hypermucoviscous ST25 and high-risk clone ST307.阿根廷产 KPC 肺炎克雷伯菌的流行情况变化：高黏液性 ST25 和高风险克隆 ST307 的出现。
J Glob Antimicrob Resist. 2019 Sep;18:238-242. doi: 10.1016/j.jgar.2019.06.005. Epub 2019 Jun 13.
5
Molecular identification of tigecycline- and colistin-resistant carbapenemase-producing Acinetobacter baumannii from a Greek hospital from 2011 to 2013.2011年至2013年从希腊一家医院分离出的对替加环素和黏菌素耐药的产碳青霉烯酶鲍曼不动杆菌的分子鉴定
J Med Microbiol. 2015 Sep;64(9):993-997. doi: 10.1099/jmm.0.000127. Epub 2015 Jul 14.
6
A ten-year surveillance study of carbapenemase-producing Klebsiella pneumoniae in a tertiary care Greek university hospital: predominance of KPC- over VIM- or NDM-producing isolates.希腊一家三级护理大学医院对产碳青霉烯酶肺炎克雷伯菌的十年监测研究：产KPC酶的分离株比产VIM酶或NDM酶的分离株更占优势。
J Med Microbiol. 2016 Mar;65(3):240-246. doi: 10.1099/jmm.0.000217. Epub 2015 Dec 23.
7
Nationwide surveillance of antimicrobial resistance among clinically important Gram-negative bacteria, with an emphasis on carbapenems and colistin: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2018.全国范围内对临床重要革兰氏阴性菌的抗生素耐药性监测，重点关注碳青霉烯类和黏菌素：2018 年台湾多中心抗生素耐药性监测（SMART）的结果。
Int J Antimicrob Agents. 2019 Sep;54(3):318-328. doi: 10.1016/j.ijantimicag.2019.06.009. Epub 2019 Jun 14.
8
Carbapenemase-producing Enterobacteriaceae in a tertiary hospital in Madrid, Spain: high percentage of colistin resistance among VIM-1-producing Klebsiella pneumoniae ST11 isolates.西班牙马德里一家三级医院的产碳青霉烯酶肠杆菌科：产 VIM-1 型肺炎克雷伯菌 ST11 分离株中多粘菌素耐药率较高。
Int J Antimicrob Agents. 2014 May;43(5):460-4. doi: 10.1016/j.ijantimicag.2014.01.021. Epub 2014 Feb 22.
9
Prevalence and molecular characterization of carbapenemase-producing gram-negative bacteria from a university hospital in China.中国某大学医院产碳青霉烯酶革兰氏阴性菌的流行状况及分子特征。
Infect Dis (Lond). 2016 Feb;48(2):138-46. doi: 10.3109/23744235.2015.1094822. Epub 2015 Oct 14.
10
Whole genome sequencing for the molecular characterization of carbapenem-resistant Klebsiella pneumoniae strains isolated at the Italian ASST Fatebenefratelli Sacco Hospital, 2012-2014.2012 - 2014年在意大利ASST Fatebenefratelli Sacco医院分离的耐碳青霉烯类肺炎克雷伯菌菌株的全基因组测序用于分子特征分析
BMC Infect Dis. 2017 Oct 10;17(1):666. doi: 10.1186/s12879-017-2760-7.

引用本文的文献

1
Invasive liver abscess syndrome complicated by carbapenem-resistant infection: a case report.侵袭性肝脓肿综合征合并耐碳青霉烯类感染：一例报告
Front Med (Lausanne). 2025 Jan 7;11:1511734. doi: 10.3389/fmed.2024.1511734. eCollection 2024.
2
Tackling Carbapenem Resistance and the Imperative for One Health Strategies-Insights from the Portuguese Perspective.应对碳青霉烯类耐药性及“同一健康”战略的必要性——来自葡萄牙视角的见解
Antibiotics (Basel). 2024 Jun 14;13(6):557. doi: 10.3390/antibiotics13060557.
3
CRISPR-Based Gene Editing in to Combat Antimicrobial Resistance.基于CRISPR的基因编辑用于对抗抗菌药物耐药性。
Pharmaceuticals (Basel). 2023 Jun 23;16(7):920. doi: 10.3390/ph16070920.
4
Antimicrobial Resistance in Romania: Updates on Gram-Negative ESCAPE Pathogens in the Clinical, Veterinary, and Aquatic Sectors.罗马尼亚的抗微生物药物耐药性：临床、兽医和水生领域中革兰氏阴性 ESCAPE 病原体的最新情况。
Int J Mol Sci. 2023 Apr 26;24(9):7892. doi: 10.3390/ijms24097892.
5
Penicillin Binding Protein 7/8 Is a Potential Drug Target in Carbapenem-Resistant Acinetobacter baumannii.青霉素结合蛋白 7/8 是耐碳青霉烯类鲍曼不动杆菌的潜在药物靶点。
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0103322. doi: 10.1128/aac.01033-22. Epub 2022 Dec 7.
6
Evasion of Antimicrobial Activity in by Target Site Modifications: An Effective Resistance Mechanism.通过靶位修饰逃避 的抗菌活性：一种有效的耐药机制。
Int J Mol Sci. 2022 Jun 13;23(12):6582. doi: 10.3390/ijms23126582.
7
Whole-Genome Sequencing Enables Molecular Characterization of Non-Clonal Group 258 High-Risk Clones (ST13, ST17, ST147 and ST307) among Carbapenem-Resistant from a Tertiary University Hospital Centre in Portugal.全基因组测序实现了对葡萄牙一家三级大学医院中心耐碳青霉烯类细菌中258型非克隆高危克隆（ST13、ST17、ST147和ST307）的分子特征分析。
Microorganisms. 2022 Feb 11;10(2):416. doi: 10.3390/microorganisms10020416.
8
First Outbreak of NDM-1-Producing ST11 in a Portuguese Hospital Centre during the COVID-19 Pandemic.新冠疫情期间葡萄牙一家医院中心首次出现产NDM-1的ST11菌株。
Microorganisms. 2022 Jan 23;10(2):251. doi: 10.3390/microorganisms10020251.
9
The Gram-Negative Bacilli Isolated from Caves- and and a Review of Their Involvement in Human Infections.洞穴来源的革兰氏阴性杆菌及其与人类感染相关性的综述
Int J Environ Res Public Health. 2022 Feb 17;19(4):2324. doi: 10.3390/ijerph19042324.
10
Pneumonia: A Rare Cause of Infection in a Patient with COVID-19.肺炎：新型冠状病毒肺炎患者感染的罕见原因
Microorganisms. 2021 Nov 17;9(11):2369. doi: 10.3390/microorganisms9112369.

本文引用的文献

1
Antimicrobial Agents That Inhibit the Outer Membrane Assembly Machines of Gram-Negative Bacteria.抑制革兰氏阴性菌外膜组装机器的抗菌剂。
J Microbiol Biotechnol. 2019 Jan 28;29(1):1-10. doi: 10.4014/jmb.1804.03051.
2
A 4.5-Year Within-Patient Evolution of a Colistin-Resistant Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Sequence Type 258.耐黏菌素肺炎克雷伯菌碳青霉烯酶-producing K. pneumoniae 序列型 258 的 4.5 年患者内进化
Clin Infect Dis. 2018 Oct 15;67(9):1388-1394. doi: 10.1093/cid/ciy293.
3
Role of association of OmpK35 and OmpK36 alteration and bla and/or bla genes in conferring carbapenem resistance among non-carbapenemase-producing Klebsiella pneumoniae.OmpK35 和 OmpK36 改变与 bla 和/或 bla 基因的关联在非碳青霉烯酶产生肺炎克雷伯菌中赋予碳青霉烯类耐药的作用。
Int J Antimicrob Agents. 2018 Dec;52(6):898-905. doi: 10.1016/j.ijantimicag.2018.03.020. Epub 2018 Apr 2.
4
Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.与碳青霉烯类耐药肠杆菌科感染的流行和治疗相关的因素：在三家三级保健医院进行的一项为期七年的回顾性研究。
Ann Clin Microbiol Antimicrob. 2018 Mar 23;17(1):13. doi: 10.1186/s12941-018-0267-8.
5
Clonal emergence of Klebsiella pneumoniae ST14 co-producing OXA-48-type and NDM carbapenemases with high rate of colistin resistance in Dubai, United Arab Emirates.在阿拉伯联合酋长国迪拜，出现了高产黏菌素耐药的同时产 OXA-48 型和 NDM 碳青霉烯酶的肺炎克雷伯菌 ST14 克隆株。
Int J Antimicrob Agents. 2018 Jul;52(1):90-95. doi: 10.1016/j.ijantimicag.2018.03.003. Epub 2018 Mar 9.
6
Uropathogenic Escherichia coli virulence factor hemolysin A causes programmed cell necrosis by altering mitochondrial dynamics.尿路致病性大肠杆菌毒力因子溶血素 A 通过改变线粒体动力学引起程序性细胞坏死。
FASEB J. 2018 Aug;32(8):4107-4120. doi: 10.1096/fj.201700768R. Epub 2018 Feb 28.
7
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.多黏菌素单用与多黏菌素联合美罗培南治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染：一项开放标签、随机对照试验。
Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.
8
Evidence to improve the treatment of infections caused by carbapenem-resistant Gram-negative bacteria.改善耐碳青霉烯类革兰氏阴性菌所致感染治疗的证据。
Lancet Infect Dis. 2018 Apr;18(4):358-360. doi: 10.1016/S1473-3099(18)30112-9. Epub 2018 Feb 16.
9
Identification of a KPC-9-producing Klebsiella pneumoniae ST258 cluster among KPC-2-producing isolates of an ongoing outbreak in Northwestern Greece: a retrospective study.在希腊西北部持续爆发的产KPC-2肺炎克雷伯菌分离株中鉴定出一个产KPC-9的肺炎克雷伯菌ST258克隆群：一项回顾性研究
Clin Microbiol Infect. 2018 May;24(5):558-560. doi: 10.1016/j.cmi.2017.12.007. Epub 2017 Dec 21.
10
Fosfomycin: Pharmacological, Clinical and Future Perspectives.磷霉素：药理学、临床及未来展望
Antibiotics (Basel). 2017 Oct 31;6(4):24. doi: 10.3390/antibiotics6040024.